{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:57:33Z","timestamp":1769597853920,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T00:00:00Z","timestamp":1463356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T00:00:00Z","timestamp":1463356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/bmt.2016.136","type":"journal-article","created":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T13:48:15Z","timestamp":1463406495000},"page":"1337-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Melphalan 200\u2009mg\/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival"],"prefix":"10.1038","volume":"51","author":[{"given":"K","family":"Sweiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Culos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Rondelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,16]]},"reference":[{"key":"BFbmt2016136_CR1","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976\u20134984.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016136_CR2","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219\u20139226.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016136_CR3","first-page":"207","volume":"56","author":"KC Abbott","year":"2001","unstructured":"Abbott KC, Agodoa LY . Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001; 56: 207\u2013210.","journal-title":"Clin Nephrol"},{"key":"BFbmt2016136_CR4","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt2016136_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2016136_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88: 360\u2013376.","journal-title":"Mayo Clin Proc"},{"key":"BFbmt2016136_CR7","unstructured":"ALKERAN (melphalan) [package insert]. Aspen: St Leonards, NSW, Australia; GlaxoSmithKline: Research Triangle Park, NC, USA. Revised 31 July 2010."},{"key":"BFbmt2016136_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","volume":"21","author":"N Shah","year":"2015","unstructured":"Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21: 1155\u20131166.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016136_CR9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V88.3.838.838","volume":"88","author":"DH Vesole","year":"1996","unstructured":"Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838\u2013847.","journal-title":"Blood"},{"key":"BFbmt2016136_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bmt.1704353","volume":"33","author":"Y Nieto","year":"2004","unstructured":"Nieto Y, Vaughan WP . Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004; 33: 259\u2013269.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016136_CR11","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","volume":"13","author":"BL Samuels","year":"1995","unstructured":"Samuels BL, Bitran JD . High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786\u20131799.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016136_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clml.2014.09.012","volume":"15","author":"N Grzasko","year":"2015","unstructured":"Grzasko N, Morawska M, Hus M . Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk 2015; 15: 187\u2013198.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbmt2016136_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s002770050499","volume":"78","author":"E Reiter","year":"1999","unstructured":"Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, Mayer G et al. Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol 1999; 78: 189\u2013191.","journal-title":"Ann Hematol"},{"key":"BFbmt2016136_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/sj.leu.2401819","volume":"14","author":"P Tosi","year":"2000","unstructured":"Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310\u20131313.","journal-title":"Leukemia"},{"key":"BFbmt2016136_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bmt.2014.226","volume":"50","author":"R St Bernard","year":"2015","unstructured":"St Bernard R, Chodirker L, Masih-khan E, Jiang H, Franke N, Kukreti V et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 2015; 50: 95\u201399.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016136_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1054\/bjoc.2001.1928","volume":"85","author":"B Sirohi","year":"2001","unstructured":"Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A et al. Glomerular filtration rate prior to high-dose melphalan 200\u2009mg\/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001; 85: 325\u2013332.","journal-title":"Br J Cancer"},{"key":"BFbmt2016136_CR17","first-page":"947","volume":"2","author":"G Tricot","year":"1996","unstructured":"Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947\u2013952.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2016136_CR18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/sj.bmt.1704948","volume":"35","author":"K Carlson","year":"2005","unstructured":"Carlson K . Melphalan 200\u2009mg\/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005; 35: 985\u2013990.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016136_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822\u2013829.","journal-title":"Br J Haematol"},{"key":"BFbmt2016136_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","volume":"75","author":"LM Knudsen","year":"2005","unstructured":"Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27\u201333.","journal-title":"Eur J Haematol"},{"key":"BFbmt2016136_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2141.2006.06191.x","volume":"134","author":"JM Bird","year":"2006","unstructured":"Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385\u2013390.","journal-title":"Br J Haematol"},{"key":"BFbmt2016136_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","volume":"15","author":"GC Parikh","year":"2009","unstructured":"Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812\u2013816.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016136_CR23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.bbmt.2014.02.013","volume":"20","author":"MN Bodge","year":"2014","unstructured":"Bodge MN, Reddy S, Thompson MS, Savani BN . Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. Biol Blood Marrow Transplant 2014; 20: 908\u2013919.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016136","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:24:52Z","timestamp":1648063492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,16]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFbmt2016136"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.136","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,16]]},"assertion":[{"value":"19 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}